A.I. Virtanen Institute for Molecular Sciences - News

Ideas for treating sleep apnea and measuring brain oxygen saturation won the Olvi Foundation Neurochallenge innovation competition this year.

The 16th FCI Symposium brought together world-renowned clinical experts and researchers to discuss the latest advances in the fight against cancer.

By combining the university's cutting-edge research capabilities with Ferring Ventures SA’s industry expertise, the partnership aims to accelerate the development of new precision medicine, specifically cell therapy treatments.

The new facility specialises in the production of a gene therapy drug for non-muscle invasive bladder cancer.

The PhD study demonstrates the importance of multiple drug discovery approaches when searching for a drug that has a beneficial disease modifying effect on TBI outcome.

UEF's role is to develop viral vector-based gene transfer methods for rare cardiovascular diseases, drug manufacturing and testing, and to contribute to repairing faulty genes through gene surgery using the latest gene editing technology.

The lecture topics range from cultural studies, education and society to AI, environmental law, aerosols, atmosphere and neuroscience.

The research marks a significant advancement in understanding how nanoplastics might transfer in human blood and interact with biological systems.

The PhD study provided valuable new insights into the genetic and functional mechanisms contributing to cardiovascular disease.

The doctoral research addressed factors related to ischemic heart disease, heart failure, xenotransplantation, and Pityriasis Rubra Pilaris (PRP), a rare inflammatory skin disorder.